US equities
|
TSLA
$395.06
▲+6.14%
MU
$908.12
▲+3.48%
SPCX
$149.31
▲+1.23%
NVDA
$215.46
▲+2.13%
META
$643.43
▲+0.13%
SNDK
$1,265.65
▲+2.23%
AAPL
$344.46
▼-0.94%
INTC
$90.89
▲+4.51%
TSLA
$395.06
▲+6.14%
MU
$908.12
▲+3.48%
SPCX
$149.31
▲+1.23%
NVDA
$215.46
▲+2.13%
META
$643.43
▲+0.13%
SNDK
$1,265.65
▲+2.23%
AAPL
$344.46
▼-0.94%
INTC
$90.89
▲+4.51%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Tiziana Life Sciences Ltd - Common Shares
(NQ:
TLSA
)
0.8817
-0.0683 (-7.19%)
Delayed Quote
Updated: 12:08 PM EDT, Oct 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tiziana Life Sciences Ltd - Common Shares
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes
April 18, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences’ (NASDAQ:TLSA) First-in-Class Foralumab Is Showing Promise
April 17, 2023
Via
ACCESSWIRE
Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID
April 13, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
EXCLUSIVE: Tiziana Life Sciences Plans To Develop Multiple Sclerosis Hopeful For Long COVID Patients
↗
April 13, 2023
Tiziana Life Sciences Ltd (NASDAQ: TLSA) plans to investigate intranasal foralumab for Long COVID. What Happened: The work is supported by foralumab's well-established role in de-activating microglia...
Via
Benzinga
Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences' (NASDAQ: TLSA) First-In-Class Foralumab Is Showing Promise
↗
April 12, 2023
Research is being done into whether there might be treatments that tackle Multiple Sclerosis (MS) through immunosuppression and a reduction of patient neuroinflammation. Anti-CD3 monoclonal antibodies...
Via
Benzinga
NIO Could Bring A Pleasant Beat This Coming Quarter
April 10, 2023
Tesla's price cuts have initiated a full on war across the EV industry, however NIO has refused to follow along. This may present even more upside for the stock
Via
MarketBeat
Topics
Electric Vehicles
Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at Prada Rong Zhai in Shanghai
April 10, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference
April 04, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Announces Positive Data on Intranasal Anti-CD3 Monoclonal Antibody in Intracerebral Hemorrhage
April 04, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer’s Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders Conference in
March 31, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Receives Sign-Off From The FDA To Proceed With Phase 2 Clinical Trial In Patients With Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
↗
March 29, 2023
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) announced it has received feedback based on the U.S. Food and Drug Administration (FDA) Type C meeting minutes related to the Phase 2 clinical trial of...
Via
Benzinga
Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
March 28, 2023
FDA Provides Positive Feedback on Intranasal Foralumab Program in Patients with Non-Active SPMS
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
March 22, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
March 21, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
March 20, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
March 17, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Highlighted in Forbes Article
March 17, 2023
Article entitled "New T Cell Antibody Treatment Improves Outcomes For Covid Patients" reviews the company's first in class foralumab, a unique Intranasal monoclonal antibody designed to treat multiple...
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Publication in Proceedings of the National Academy of Sciences (PNAS) Illustrating the Immunological Basis of the Mechanism of Action for Intranasal Foralumab
March 08, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
7 Thrilling Stocks to Buy for Aggressive Investors
↗
March 06, 2023
Sometimes you need to be aggressive to unlock the best returns for your portfolio. Just be smart when looking for the best stocks to buy.
Via
InvestorPlace
Proactive research analyst says Tiziana Life Sciences "moving forward quite nicely"
February 09, 2023
Proactive research analyst says Tiziana Life Sciences "moving forward quite nicely"
Via
News Direct
Proactive research analyst says Tiziana Life Sciences "moving forward quite nicely"
February 09, 2023
Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a 2023 Clinical Outlook for clinical stage biotechnology company Tiziana Life Sciences Ltd (NASDAQ:TLSA). He gives his...
Via
TheNewswire.com
Tesla HODLs Bitcoin — But Sticks To Dogecoin-Only Crypto Payments Policy
↗
January 26, 2023
Electric car maker Tesla Inc (NASDAQ: TLSA) continues to hold on to Bitcoin (CRYPTO: BTC) but only accepts Dogecoin (CRYPTO:
Via
Benzinga
Tiziana Life Sciences Announces IND filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung Cancer
January 04, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Posts Additional Clinical Improvements In Second Patient with Multiple Sclerosis
↗
January 03, 2023
Via
Benzinga
Tiziana Life Sciences Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) After Eleven Months of Dosing with Intranasal Foralumab
January 03, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Updated Interim Results for the Six Months Ended 30 June 2022
December 29, 2022
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Interim Results for the Six Months Ended 30 June 2022
December 27, 2022
Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana to Participate in January Investor Meetings
December 16, 2022
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Completion of Prerequisite Pre-Clinical Safety Study
December 15, 2022
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Ltd. Granted 180-day Extension by Nasdaq to Meet Minimum Bid Price Requirements
December 14, 2022
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
